Table 1.
Inhibitors of the PD-1/PD-L1 signaling pathway
| Name | Target | Research stage | Indications |
|---|---|---|---|
| Nivolumab [16] | PD-1 | On the market | NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, etc. |
| Pembrolizumab [18] | PD-1 | On the market | NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, etc. |
| Cemiplimab [23] | PD-1 | On the market | Cutaneous squamous cell carcinoma, NSCLC, basal cell carcinoma |
| Atezolizumab [20] | PD-L1 | On the market | NSCLC, bladder cancer, triple-negative breast cancer, etc. |
| Avelumab [22] | PD-L1 | On the market | Merkel cell carcinoma, urothelial carcinoma |
| Durvalumab [21] | PD-L1 | On the market | NSCLC, bladder cancer, small cell lung cancer |
| Envafolimab [218] | PD-L1 | In clinical trials | Soft tissue sarcoma, biliary tract cancer |
| Sintilimab [24] | PD-1 | On the market | NSCLC, liver cancer, gastric cancer |
| Toripalimab [25] | PD-1 | On the market | Nasopharyngeal carcinoma, melanoma, lung cancer |